Alivio Therapeutics is pioneering a new way to treat inflammatory diseases based on precisely tuning the immune system at the site of disease.
Alivio Therapeutics is developing the only inflammation-targeting technology that exists which allows for selective modulation of the immune system at the site of inflammation while avoiding systemic immunosuppression, which is a long sought-after goal in the treatment of auto-immune disease. The platform has been validated in ten different preclinical models of inflammatory disease with publications in top tier journals including Science Translational Medicine and Nature Communications.
The company is developing an internal pipeline of drugs for difficult-to-treat gastrointestinal diseases that leverage the unique nature of the platform. This includes inflammatory pouchitis, an orphan disease for which there are few effective treatment options. Alivio will also seek to realize value from its broader platform primarily using partnerships. For example, Alivio was awarded a $3.3 M grant from the Department of Defense (DoD) to develop a product for treatment of interstitial cystitis for which Alivio subsequently entered a partnership in which Alivio will receive up to $14.75 million in upfront and near-term exercise payments and is eligible to receive royalties on product sales and over $260 million in research and development milestones. The opportunity is protected by a portfolio of IP including issued claims protecting the broader platform. PureTech Health co-founded Alivio together with Bob Langer (MIT) and Jeffrey Karp (Brigham and Women’s Hospital).
FOUNDERS & LEADERSHIP TEAM
Jeff Karp, Ph.D.
CO-FOUNDER & Member of the Scientific Advisory Board
Dr. Jeff Karp is a co‐founder of Alivio Therapeutics and is a Professor at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 100 peer‐reviewed papers, has given over 200 national and international ...
Robert Langer, Sc.D.
CO-FOUNDER, Member of the Scientific Advisory Board & Board of Directors
Dr. Robert Langer is a co-founder of Alivio Therapeutics and is known for his groundbreaking discoveries in the fields of polymer chemistry, controlled drug delivery, and tissue engineering. He is the David H. Koch Institute Professor at the Massachusetts Institute of Technology...
Ivana Magovcevic‐Liebisch, Ph.D., J.D.
Member of the Board of Directors
Dr. Ivana Magovcevic-Liebisch is Executive Vice President and Chief Business Officer of Ipsen. She was previously Senior Vice President and Head of Global Business Development at Teva Pharmaceuticals. In this capacity, Ivana was responsible for the execution of transactions identified by Teva’s R&D, Global Franchises ...
Eric Elenko, Ph.D.
CO-FOUNDER & Member of the Board of Directors
Dr. Eric Elenko is a co-founder of Alivio Therapeutics and the Chief Innovation Officer at PureTech Health. Dr. Elenko has led the development of a number of programs, including Akili Interactive Labs, Gelesis, Karuna Pharmaceuticals and Sonde Health...
Greg Zugates, Ph.D.
vice president of research and development
Dr. Zugates is the Vice President of Research and Development for Alivio Therapeutics. He joins Alivio after spending the last 10 years at Arsenal Medical, a medical device company in Watertown, MA. During this time, he has been a lead inventor in developing Arsenal's biodegradable ...
ALEKS RADOVIC-MORENO, PH.D.
Dr. Radovic-Moreno is a co-founder of Alivio Therapeutics and a Senior Vice President at PureTech Health. He is also a co-founder of Vor Biopharma, an immuno-oncology company which completed a $42M Series A financing in February 2019. He was previously a Research Scientist at the biotech startup Exicure (formerly AuraSense Therapeutics), where he was a lead inventor of the company's core immunotherapy ...
Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter KV, Sherman NE, Amirault J, Wang Y, Riegel L, He X, Rui TS, Valic M, Vemula PK, MIranda OR, Levy O, Gravallese EM, Aliprantis AO, Ermann J, Karp JM. Towards an arthritis flare-responsive drug delivery system. Nat Commun 2018 Apr 3:9(1):1275
Zhang S, Ermann J, Succi MD, Zhou A, Hamilton MJ, Cao B, Korzenik JR, Glickman JN, Vemula PK, Glimcher LH, Traverso G, Langer R, and Karp JM. An inflammation‐targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci Transl Med 2015 Aug 12:7(300):300ra128
Gajanajake T, Olariu R, Leclere FM, Dhayani A, Yang Z, Bongoni AK, Banz Y, Constantinescu MA, Karp JM, Vemula PK, Rieben R, Voegelin E. A single localized dose of enzyme‐responsive hydrogel improves long‐term survival of a vascularized composite allograft. Sci Transl Med 2014 Aug 13:6(249):249ra110
In the News
Jun 5, 2018: Enzyme-Responsive Hydrogels May Help Treat Arthritis (JAMA)
May 3, 2018: Hydrogels on Demand (BioCentury)
Jul 22, 2016: The Gel That’s Revolutionizing Pain Treatment (The Atlantic)